Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2

Cynthia Melissa Valerio1*, Juliana Severo de Almeida1, Rodrigo Oliveira Moreira1, Luiza Barreto. S. Aguiar1, Priscila O. Siciliano1, Denise P. Carvalho2 and Amelio F. Godoy-Matos1

Abstract

Background: Dipeptidyl peptidase-4 (DDP4) is an enzyme responsible for glucagon-like peptide-1 inactivation and plays an important role in glucose metabolism.

Objective: The aim of this study was to evaluate DPP4 levels in patients with familial partial lipodystrophy type 2 (FPLD2) and correlate it with body fat distribution.

Methods: Fourteen patients with FPLD2 were selected to participate in this study and matched to a healthy control group (n = 8). All participants had anthropometrical data registered. Body adiposity index (BAI) was used to evaluate fat distribution in this population. Body fat content and distribution were analyzed by dual X-ray absorptiometry (DXA). Biochemical exams, including DPP4 levels, were performed in all individuals.

Results: Despite the same body mass index, lipodystrophic patients had a significant lower hip (median 92.0 vs 94.5; p = 0.028), HDL cholesterol (42.6 ± 10.4 vs 66.1 ± 16.0; p < 0.01) and BAI (24.1 ± 2.8 vs 29.0 ± 3.7; p = 0.02), suggesting that BAI was able to catch differences in fat distribution between groups. On the other hand, patients with FPLD2 presented significant higher levels of insulin (median 11.2 vs 5.3; p = 0.015), triglycerides (184.9 ± 75.4 vs 89.1 ± 51.0; p < 0.01) and DPP4 (4.89 ± 0.92 vs 3.93 ± 1.08; p = 0.04). A trend toward an inverse statistical significance was observed between DPP4 levels and BAI (r = −0.38; p = 0.072). In the lipodistrophic group, a significant correlation was found between DPP4 levels and percentage of total body fat (r = 0.86; p = 0.0025) and android fat (r = 0.78; p = 0.014).

Conclusions: Patients with FPLD2 exhibit an increase in DDP4 levels in comparison to a healthy control group. The increase in the levels of this enzyme does not seem to be related to the diagnosis of diabetes and might be associated with an increase in central fat (estimated using BAI and measured using DXA). These results might be used to reinforce the concept that DDP4 is an adipokine related to central fat distribution.

Keywords: Dipeptidyl peptidase-4, Lipodystrophy, Adipokines

Background

Dipeptidyl peptidase-4 (DPP4) is a ubiquitous enzyme knowing to cleave several peptides, including glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) [1]. GLP1 and GIP are released from the intestinal mucosa and respond for ~60% of postprandial insulin secretion, also known as incretin effect [2]. DPP4 inhibitors increase active GLP-1 and GIP, modulating pancreatic α and β-cell function, and therefore are part of the target therapeutics for type 2 diabetes [2, 3].

*Correspondence: dracynthiavalerio@gmail.com
1 Metabolism Unit, Instituto Estadual de Diabetes e Endocrinologia (IEDE), Rua Moncorvo Filho 90, Rio de Janeiro, RJ CEP 20211-340, Brazil
Full list of author information is available at the end of the article

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Recently, Lamers et al. [4] demonstrated that DPP4 is expressed and released by mature adipocytes, suggesting that it may be a new adipokine. In an in vitro experiment, DPP4 inhibited insulin-induced Akt phosphorylation, thus linking DPP4 levels to insulin resistance (IR). Furthermore, these authors demonstrated that plasma DPP4 levels were increased in obese patients and were directly related to BMI, leptin and fasting insulin levels, and negatively to adiponectin [4]. Moreover, in adipocytes obtained by biopsy from obese patients, DPP4 expression was five times more evident in visceral in comparison to subcutaneous fat [4]. This relationship between DDP-4 and adipose tissue was re-examined by Sell et al. [5] and similar results were yielded.

Adipokine levels may be altered in states of excessive or decreased body adiposity. We have been studying lipodystrophic patients trying to characterize how adipokines behave in such model of adipose tissue scarcity. In these patients, leptin and retinol binding protein 4 (RBP4) levels seem to be decreased, but have not related with indexes of IR [6].

Familial partial lipodystrophy type 2 (FPLD2) is an inherited disease characterized by lack of peripheral adipose tissue and fat deposition in ectopic sites, such as liver and muscle, which is associated with IR and diabetes [7]. As an adipokine, DPP4 levels may be altered in such models. To the best of our knowledge, there is no published data on DPP4 and FPLD2. Therefore, the aim of this study is to evaluate DPP4 levels in patients with FPLD2.

Methods
Fourteen patients with FPLD2 were selected to participate in this study. FPLD2 diagnosis was confirmed by molecular analysis of LMNA gene (ABI Prism 3100 Genetic Analyzer, Applied Biosystems, Foster City, CA) provided by the Molecular Endocrinology Laboratory of Paulista Medical School. All patients had a missense mutation in LMNA gene: ten patients harbored the heterozygous variation p.R482W; in three patients, the identified mutation was p.R482Q (c.1445G > A) and one patient exhibited a novel heterozygous variant in exon 8. A control group (two healthy men and six healthy women) was carefully and sequentially selected in order to match the lipodystrophic group by body mass index (BMI) and age. A written informed consent was obtained from all participants after procedures involved in the study were fully explained. The ethic committee of the institution approved the protocol.

Exclusion criteria were as follows: current use or in the last six months of DPP4-inhibitors or GLP-1 agonists, end stage kidney disease, liver failure and heart failure above stage II Functional classification of the New York Heart Association (NYHA).

Anthropometrical examination
All patients had the following anthropometrical data registered: body weight (Kg), height (m), waist circumference (WC), and waist-to-hip ratio (WHR). BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m²). Waist circumference was determined at the midpoint between the lowest rib and the iliac crest. WHR was defined as the ratio of waist girth to the largest circumference of the hips, measured at the trochanter major. Body adiposity index (BAI) was calculated according to the formula proposed by Bergman et al. [8]: BAI = (Hip/Height^{1.5}) − 18.

Body fat analysis
Dual X-ray absorptiometry (DXA) scan (LUNAR PRODIGY ADVANCE software version 9.5, LNR 41569 model; GE Medical Systems, Waukesha, WI) was used to estimate human body fat content. Fat quantity and distribution were quantified in percentage (%): total and truncular fat, upper and lower limbs fat, android and gynoid fat mass. Whole body DXA scans were obtained using manufacturer’s recommendations for subject positioning, scan protocols, and scan analysis.

Laboratory evaluation
Routine laboratory tests were performed by CientificaLab Laboratory: fasting plasma glucose (FPG—enzymatic colorimetric method), Hemoglobin A1c [HbA1c—high performance liquid chromatography (HPLC)], cholesterol and fractions (Enzymatic colorimetric) and insulin (electrochemiluminescence). DPP4 was measured utilizing a commercial ELISA kit of dipeptidyl Peptidase IV (E90884Hu) USCN Life Science Inc. Houston, USA.

Insulin resistance was evaluated by HOMA-IR (homeostasis model assessment) calculated by the formula [Insulin (mU/L) × Glucose (mmol/L)/22.5] and β-cell function (HOMA-β) by the formula [insulin (mU/L) × 20/Glucose (mmol/L) − 3.5]. Insulin sensitivity was evaluated by QUICKI (quantitative insulin sensitivity check inbox) calculated by the formula [1/(log Insulin Glucose + log)].

Statistical analysis
Statistical analysis was performed with GraphPad InStat 3.00 for Windows 95 (GraphPad Software, San Diego, California, USA). Kolmogorov–Smirnov test was used to identify non-parametric variables. The unpaired t test was used for parametric variables and Mann–Whitney for non-parametric variables. The strength of the linear relationship between two continuous variables was evaluated by means of the Pearson’s correlation coefficient or
Spearman's correlation coefficient. The level of statistical significance was 5%.

**Results**

Fourteen women with FPLD2 were evaluated in our study. Patients belonged to seven different families and have been previously characterized [9]. In brief, six patients had the diagnosis of lipoatrophic diabetes with average duration of 10.8 years since diagnosis. Three of them were in use of metformin, one was using sulphonylurea and one was on insulin and pioglitazone therapy. None of the patients in the lipodystrophic group were using any medications that could affect DPP4 levels, as incretinomimetic agents. Table 1 presents the comparison between control group and lipodystrophic subjects. None of the subjects included in control group had diabetes. Despite the same age and BMI, lipodystrophic patients had significant differences in insulin sensitivity (insulin, HOMA-IR and QUICKI), anthropometric (i.e. hip) and metabolic parameters (i.e. HDL cholesterol and triglycerides). For the same BMI, BAI was able to catch differences in total body fat content between groups. DPP4 was increased in patients with FPLD2 in comparison to the control group.

Additional analyses were performed to investigate whether the diagnosis of diabetes would impact in DPP4 levels. Eight patients with FPLD2 without diabetes were compared to the healthy control group and they presented significantly higher levels of DPP4 (5.1 ± 0.7 vs 3.9 ± 1.0; p = 0.022). Within FPLD2 group, patients with diabetes (n = 6) were compared to patients without diabetes (n = 8). No difference in DPP4 was found in these patients (4.5 ± 1.1 vs 5.1 ± 0.7; p = 0.28).

Correlation analysis was used to determine how anthropometric measurements and metabolic variables correlated with DPP4 levels. In our sample, no correlation could be demonstrated between DPP4 and hip (r = −0.29; p = 0.18), WHR (r = 0.03; p = 0.89), insulin (r = 0.16; p = 0.49), HOMA-β (r = 0.27; p = 0.23), HOMA-IR (r = 0.13; p = 0.56), QUICKI (r = −0.19; p = 0.40), HDL Cholesterol (r = −0.14; p = 0.51) and triglycerides (r = 0.30; p = 0.17). A trend toward an inverse statistical significance was observed between DPP4 and BAI (r = −0.38; p = 0.072; Fig. 1).

Body fat was also evaluated using DXA in nine patients with FPLD2. In these patients, a significant correlation was found between DPP4 levels and percentage of total body fat and (r = 0.86; p = 0.0025) and android fat (r = 0.78; p = 0.014).

**Discussion**

Lipodystrophic syndromes are characterized by scarcity of subcutaneous adipose tissue in a generalized or localized fashion [7]. We have previously characterized body fat distribution by DXA in patients with generalized and

| Table 1 Clinical and biochemical variables in a sample of patients with familial partial lipodystrophy type 2 (FPLD2) in comparison to control group |
|---|---|---|
| **FLPD (n = 14)** | **Control (n = 8)** | **P value** |
| Age (years) | 40.0 ± 12.6 | 31.3 ± 17.7 | 0.19 |
| Gender (female) | 12 | 6 | 0.60 |
| Weight (kg) | 66.2 ± 100 | 60.1 ± 88 | 0.16 |
| BMI (kg/m²) | 24.1 | 23.4 | 0.40 |
| Waist (cm) | 81.8 ± 80 | 80.7 ± 10.7 | 0.79 |
| Hip (cm) | 92.0 | 94.5 | 0.028 |
| BAI (r = 0.38; p = 0.072) | 79–96 | 89–100 | |
| Waist to Hip Ratio (WHR) | 0.91 ± 0.06 | 0.84 ± 0.10 | 0.08 |
| BAI | 24.1 ± 2.8 | 29.0 ± 3.7 | 0.002 |
| Glucose (mg/dL) | 90.5 | 89.0 | 0.56 |
| 70.0–184.0 | 81–101 | |
| Insulin (mU/L) | 11.2 | 5.5 | 0.015 |
| 4.8–42.9 | 3.1–13.3 | |
| HOMA-β | 40.4 ± 19.2 | 21.4 ± 11.9 | 0.04 |
| HOMA-IR | 2.2 | 1.1 | 0.025 |
| QUICKI | 0.32 ± 0.03 | 0.37 ± 0.03 | 0.02 |
| HOMA-IR | 42.6 ± 104 | 66.1 ± 16.0 | <0.01 |
| Triglycerides (mg/dL) | 184.9 ± 75.4 | 89.1 ± 51.0 | <0.01 |
| HbA1c (%) | 5.6 | 5.4 | 0.14 |
| 5.2–9.1 | 4.8–6.1 | |
| DPP4 (ng/mL) | 4.89 ± 0.92 | 3.93 ± 1.08 | 0.04 |

Data are presented as mean ± SD, except BMI, hip, glucose, insulin, HOMA-IR and HbA1c that are presented as median (lower limit–upper limit).

BMI body mass index, WHR waist to hip ratio, BAI body adiposity index, HOMA-β homeostasis model assessment β, HOMA IR homeostasis model assessment insulin resistance, QUICKI quantitative insulin sensitivity check inbox, DPP4 Dipeptidyl peptidase-4

![Fig. 1](image-url)  
Correlation between dipeptidyl peptidase-4 (DPP4) levels and body fat distribution, measured by body adiposity index (BAI; r = −0.38; p = 0.072)
partial lipodystrophy and have demonstrated that a central to peripheral fat ratio, named fat mass ratio (FMR) [10, 11] and BAI [12], may be useful to investigate fat distribution in these patients [10–12]. Our main results were that individuals with FPLD2 do have increased levels of DPP4 and that these levels might correlate with body fat distribution measured by DXA and estimated by BAI.

As stated above, it has been previously demonstrated that BAI inversely correlates with FMR in patients with FPLD2 [12] suggesting, at least in this population, that lower BAI scores may also reflect higher central-to-peripheral fat ratio (as a main anthropometric measure in BAI equation is hip circumference). In the present study, patients with FPLD2 had lower BAI and increased levels of DPP4. It has also been demonstrated a trend toward significance in the inverse correlation between BAI and DPP4 and that body fat content correlates with DPP4 levels, at least in patients with FPLD2. Taken together, these findings support the concept of DPP4 as an adipokine related to central fat. Indeed, more recently it was demonstrated that DPP4 is expressed in subcutaneous adipose tissue (SAT) as well as in visceral adipose tissue (VAT), with VAT exhibiting higher expression [5]. Ex vivo release of DPP4 from adipose explants was higher in VAT than SAT. Furthermore, circulating DPP4 correlated with the amount of VAT and, for the same BMI, insulin-resistant obese patients had higher DPP4 levels than insulin-sensitive obese patients [5]. Tanaka et al. [13] had previously demonstrated that serum DPP4 levels were positively correlated with visceral fat area (evaluated with computed tomography scan) in 135 men with type 2 diabetes. In their study, the positive association of the adipokine with visceral fat area remains unaffected even after adjusting for various parameters as average duration of diabetes, HbA1c and BMI, reinforcing an important correlation of body fat distribution with DPP4 levels.

Other adipokines have already been studied in FPLD2. Wong et al. [14] demonstrated that adiponectin, leptin and interleukin 6 (IL-6) are decreased, unlike the tumor necrosis factor-α (TNF-α) that is increased. These authors suggested that these changes are important determinants of IR. We have previously showed that RBP4 and leptin were decreased in FPLD2 and the later negatively correlated with WHR, what supported its relationship with the amount and distribution of body fat, but not with IR [6]. In the same way, the present data suggest that DPP4 can be a marker of adiposity and fat distribution, but does not associate with IR.

It is possible that liver fat deposition is a more plausible explanation for the correlation between these adipokines and IR. A study in patients with nonalcoholic steatohepatitis (NASH) showed an increase in serum activity of DPP4 [15]. Furthermore, the intensity of immunofixation of DPP4 in liver and its serum activity correlated with the histological grade of steatosis and NASH. Firneisz et al. [16] confirmed the increased activity of DPP4 in non-diabetic and diabetic patients with fatty liver disease. Unfortunately, the severity of liver disease was not accessed in this study and further studies are necessary to investigate this hypothesis.

An increased DDP4 concentration in patients with FPLD2 may have important implications for the physiopathology and treatment of diabetes in this population. Although no study has already been performed to investigate the impact of DPP4 inhibitors and/or GLP-1 agonists/analogs in lipodystrophy, it seems reasonable to suppose that they might be useful in these individuals, in a way that resembles its efficacy in type 2 diabetes and obesity.

Our study has some limitations. First, only a small number of individuals were included in each group. The small size our sample might help justifying some of our findings, including the lack of association between DPP4 levels and markers of insulin resistance, for instance. Second, DXA was only performed in a limited number of patients in the FPLD2 group. However, the strong relationship found between DPP4 levels and android fat, taken together with BAI, strengthens the findings of our study.

Conclusions
In conclusion, patients with FPLD2 exhibit an increase in DDP4 levels in comparison to a healthy control group. The increase in the levels of this enzyme does not seem to be related to the diagnosis of diabetes and might be associated with an increase in central fat (estimated using BAI and measured using DXA). These results might be used to reinforce the concept that DPP4 is an adipokine related to central fat distribution. Further studies are necessary to clarify the role of DPP4 inhibitors in the treatment of lipodystrophic patients.

Abbreviations
DPP4: dipeptidyl peptidase-4; FPLD2: familial partial lipodystrophy type 2; BAI: body adiposity index; FMR: fat mass ratio; GLP-1: glucagon-like peptide-1; GIP: gastric inhibitory polypeptide; DXA: dual energy X-ray assessment; RBP-4: retinol binding protein 4.

Authors’ contributions
DPC carried out the immunoassay, ROM participated in the design of the study and performed the statistical analysis, LBPSA and POS conceived the study and acquired data, CMV, JSA and AFG conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details
Metabolism Unit, Instituto Estadual de Diabetes e Endocrinologia (IEDE), Rua Moncorvo Filho 90, Rio de Janeiro, RJ CEP 20211-340, Brazil. 2 Endocrine
Acknowledgement
The authors are grateful to Aegerion Pharmaceuticals for purchasing the article-processing charges. The company’s employees were not involved in the study design, writing the paper or approval of the submitted version of the manuscript.

Competing interests
The authors declare that they have no competing interests. Acknowledgement: The authors are grateful to Aegerion Pharmaceuticals for purchasing the article-processing charges. The company’s employees were not involved in the study design, writing the paper or approval of the submitted version of the manuscript.

Ethics approval and consent to participate
The ethic committee of the Instituto Estadual de Diabetes e Endocrinologia approved the protocol.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 9 September 2016   Accepted: 18 April 2017
Published online: 24 April 2017

References
1. Mentlein R. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.
3. Salvatore T, Carbonara O, Cozzolino D, Torella R, Sasso FC. Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors. Curr Diabetes Rev. 2009;5:92–101.

4. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60:1917–25.
5. Sell H, Bühler M, Kloting N, Schlich R, Willems M, Ruppe F, Knoefel WT, Dietrich A, Felding BA, Arner P, Frayn KN, Eckel J. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care. 2013;36(12):4083–90.
6. Godoy-Matos AF, Moreira RO, MacDowell R, Bennett I, Mory PB, Moises RS. Serum retinol protein 4 in patients with familial partial lipodystrophy. Clin Biochem. 2009;42:1183–6.
7. Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313–25.
8. Bergman RN, Stefanovski D, Buchanan TA, Sumner AE, Reynolds JC, Sebring NG, et al. A better index of body adiposity. Obesity. 2011;19:1083–9.
9. Mory PB, Crispim F, Freire MB, Salles JE, Valério CM, Godoy-Matos AF, et al. Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations. Eur J Endocrinol. 2012;167:423–31.
10. Valério CM, Godoy-Matos AF, Moreira RO, et al. Dual-energy X-ray absorptiometry study of body composition in patients with lipodystrophy. Diabetes Care. 2007;30:1857–9.
11. Valério CM, Zajdenverg L, de Oliveira JE, Mory PB, Moyses RS, Godoy-Matos AF. Body composition study by dual-energy x-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation. Diabetes Metab Syndr. 2012;4(1):40. doi:10.1186/1758-5996-4-40.
12. Godoy-Matos AF, Moreira RO, Valério CM, Mory PB, Moises RS. A new method for body fat evaluation, body adiposity index, is useful in women with familial partial lipodystrophy. Obesity (Silver Spring). 2012;20:440–3.
13. Tanaka S, Kaniawaza I, Notsu M, et al. Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016;116:1–6.
14. Wong SP, Huda M, English P, Bagirotta A, et al. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Diabetologia. 2005;48:2641–9.
15. Balaban YH, Korkusuz P, Simsek H, Gedikoglu G, Pinar A, et al. Dipeptidyl-peptidase IV (DPP IV) in NASH patients. Ann Hepatol. 2007;6:242–50.
16. Finneiz G, Varga T, Lengyel G, Fehér J, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS ONE. 2010;5:e12226.